tbuckley/cabot-search huggingface dataset:
OA22.01 STELLAR - Interim Results of a Phase 2 Trial of TTFields with Chemotherapy for First Line Treatment of Malignant Mesothelioma
Authors: Federica Grosso, Jarek Mądrzak, Rodryg Ramlau, Susana Cedres Perez, Lucio Crinò, Antonio Chella, Manlio Mencoboni, Birgitta Hiddinga, Giovanni Ceresoli
Journal: Journal of Thoracic Oncology (2017)
P1.02-025 Evaluation of NGS and RT-PCR Methods for ALK Assessment in European NSCLC Patients: Results from the ETOP Lungscape Project
Authors: Stephen Finn, Igor Letovanec, Panagiota Zygoura, Paul Smyth, Alex Soltermann, Lukas Bubendorf, Ernst-Jan Speel, Antonio Marchetti, Daisuke Nonaka, Kim Monkhorst, Henrik Hager, Miguel Martorell, Aleksandra Sejda, Richard Cheney, Javier Hernandez-Losa, Eric Verbeken, Walter Weder, Spasenija Savic, Alessia Di Lorito, Atilio Navarro, Enriqueta Felip, Arne Warth, Paul Baas, Peter Meldgaard, Fiona Blackhall, Anne-Marie Dingemans, Hendrik Dienemann, Rafal Dziadziuszko, Johan Vansteenkiste, Thomas Geiger, Jon Sherlock, Jeoffrey Schageman, Urania Dafni, Roswitha Kammler, Keith Kerr, Erik Thunnissen, Solange Peters, Rolf Stahel
Journal: Journal of Thoracic Oncology (2017)
P2.03a-022 QOL and Febrile Neutropenia: Japanese Phase 2 Trial of Docetaxel with/out Antiangiogenic Agent in 2nd Line NSCLC
Authors: Yukie Omori, Alan Brnabic, Narayan Rajan, Jangchul Park, Sotaro Enatsu, Akira Inoue
Journal: Journal of Thoracic Oncology (2017)
Association of HLA-G Haplotype Risk Model with Overall Survival In Acute Myeloid Leukemia Patients
Authors: Anja Volbracht, Juergen R Novotny, Crista Ochsenfarth, Magdalena Switala, Ulrich Frey, Peter A Horn, Ulrich Duehrsen, Vera Rebmann, Holger Nuckel
Journal: Blood (2010)
P3.02c-057 Viroimmunotherapy with Vesicular Stomatitis Virus Expressing Interferon-β (Vsv-IFNβ) in a Murine Model of NSCLC
Authors: Manish Patel, Blake Jacobson, Alexander Dash, Kareem Ismail, Yan Ji, Robert Kratzke
Journal: Journal of Thoracic Oncology (2017)
The Tyrophostin Adaphostin (NSC680410) Inhibits Multiple Myeloma Bone Marrow Angiogenesis In Vitro and In Vivo.
Authors: Klaus Podar, Jing Zhang, Marc S. Raab, Sonia Vallet, Mariateresa Fulciniti, Martin Sattler, Yutaka Ikeda, Dharminder Chauhan, Kenneth C. Anderson
Journal: Blood (2007)
Critical Evaluation of Diverse Clinical, Laboratory, Radiological and Histological Parameters Indicating Gastrointestinal Involvement for Diagnosis of Indolent and Aggressive Systemic Mastocytosis
Authors: Georgia Metzgeroth, Juliana Schwaab, Martina Teichmann, Alexander Marx, Henrik J. Michaely, Hans Peter Horny, Nicholas C.P. Cross, Andreas Hochhaus, Wolf Karsten Hofmann, Andreas Reiter
Journal: Blood (2011)
P27 Evaluation and baseline characteristics of patients with chronic thromboembolic disease in a single referral centre
Authors: EM Swietlik, D Taboada, A Ruggiero, E Bales, L Harlow, A Fletcher, JE Cannon, K Sheares, DP Jenkins, J Pepke-Zaba, M Toshner
Journal: Thorax (2016)

<h3>Introduction</h3> Chronic thromboembolic disease (CTED) is a consequence of failure of thrombus resolution following pulmonary embolism. Thrombotic material becomes fibrosed, resulting in chronic vascular occlusion without pulmonary hypertension. The prevalence and incidence of the condition is unknown and the mechanisms behind exercise intolerance are poorly understood. Surgical management in selected cases may significantly improve symptoms and patient functioning.<sup>1</sup> <h3>Methods</h3> We prospectively evaluated baseline characteristics of patients with CTED in a single referral centre between January 2015 and June 2016. Newly referred patients with suspected CTED underwent a standard assessment as delineated in international guidelines with a minimum of 2 imaging modalities, resting and exercise right heart catheterisation and additionally incremental cardiopulmonary exercise testing (CPET). All patients were assessed in a pulmonary endarterectomy (PEA) MDT. <h3>Results</h3> 128 patients were diagnosed with CTEPH or CTED from our referral centre. 28 patients were referred with suspected CTED due to ECHO findings. Of these 21 patients were confirmed to have CTED at right heart catheterization and 16 underwent full investigation protocol and were analysed. Patients with CTED were younger than contemporary cohorts of CTEPH<sup>2 </sup>and were more likely to have a past medical history of VTE (94%). Patients with CTED had normal resting haemodynamics, preserved RV function at rest and normal NT-proBNP (Table1). After careful review of each patient’s investigations only 5 of the 21 patients with CTED were offered PEA. <h3>Conclusions</h3> Patients with CTED represent a significant proportion of the new referrals to our specialist centre. Surgery is deemed an appropriate therapeutic approach in a small subset of patients with significant functional and symptomatic impairment. The natural history of CTED is unclear so any discussion of surgery needs to carefully consider surgical risk of death and morbidity against the potential for symptomatic improvement. <h3>References</h3> Taboada D, <i>et al</i>. Outcome of pulmonary endarterctomy in symptomatic chronic thromboembolic disease. <i>ERJ</i> 2014;<b>44</b>(6):1635–45. Pepke-Zaba J, <i>et al</i>. Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Results from and international prospective registry. <i>Circulation</i> 2011;<b>124</b>(18):1973–81.
Thymolipoma simulating cardiomegaly: Diagnostic usefulness of computed tomography.
Authors: Koshi Matsuyama, Toshiyuki Nakagawa, Yutaka Horio, Hiroaki Hongo, Yoshimasa Miyauchi, Hirofumi Yasue
Journal: Circulation (1986)

We reported the case of a 46-year-old man with thymolipoma whose chest X-ray initially suggested cardiomegaly. Computed tomography (CT) clearly demonstrated the existence of a large mass adjoining the left ventricular wall in the mediastinum. CT also allowed estimation of the character of the mass including its size, extent, and consistency. At thoracotomy, the tumor was excised and thymolipoma was diagnosed histopathologically.
Alloreactivity of Virus Specific T-Cells.
Authors: Avital L. Amir, Lloyd J.A. D’Orsogna, Marleen M. van Loenen, Dave L. Roelen, Ilias I.N. Doxiadis, Frans H.J. Claas, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk
Journal: Blood (2008)
The Scent of Cancer
Authors: David P Steensma
Journal: Annals of Internal Medicine (2010)

On Being a Doctor3 August 2010The Scent of CancerDavid P. Steensma, MDDavid P. Steensma, MDFrom Dana-Farber Cancer Institute, Boston, MA 02115.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-153-3-201008030-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Use your five senses … Learn to see, learn to hear, learn to feel, learn to smell, and know that by practice alone you can become expert.—William OslerAncestral portraits lining the halls of European manor houses often reveal a familial anatomical hallmark—a multigenerational overbite, perhaps, or a peculiar widow's peak, or elephantine earlobes—distinctive physical traits that mark portrait sitters as members of the clan. My own kin's hereditary idiosyncrasy is a prominent nose, which is a long-standing family joke—so much so that at a recent family reunion, cousins and aunts arrived wearing custom-made T-shirts featuring the familiar familial trait ... Author, Article, and Disclosure InformationAffiliations: From Dana-Farber Cancer Institute, Boston, MA 02115.Corresponding Author: David P. Steensma, MD, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, 44 Binney Street, Suite D1B30, Boston, MA 02115; e-mail, [email protected]harvard.edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Scent of Cancer Robert E. Jackson The Scent of Cancer Marc P. van der Schee , Lisette N. Venekamp , and Peter W.A. Kunst Metrics Cited byThe Scent of CancerRobert E. Jackson, MDThe Scent of CancerMarc P. van der Schee, MSc, Lisette N. Venekamp, MD, and Peter W.A. Kunst, MD, PhD 3 August 2010Volume 153, Issue 3Page: 206-207KeywordsCancer treatmentNursing homesSalicylatesSmellSweatTalcTyphoidUrineWine ePublished: 3 August 2010 Issue Published: 3 August 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
P2.04-037 Solitary Fibrous Tumor of the Pleura Associated with Severe Hypoglicemia: The Doege-Potter Syndrome
Authors: Luigi Ventura, Letizia Gnetti, Cesare Braggio, Paolo Carbognani, Michele Rusca, Enrico Maria Silini, Luca Ampollini
Journal: Journal of Thoracic Oncology (2017)
Characterization of Endothelial Progenitor Cells in Healthy Subjects: Effects of Different Factors on Immunophenotype and Clonogenic Potential.
Authors: Alessandra Giorgetti, Michele M. Ciulla, Michela Cortiana, Ilaria Silvestri, Elisa Montelatici, Rosaria Giordano, Roberta Paliotti, Agostino Cortelezzi, Paolo Rebulla, Lorenza Lazzari
Journal: Blood (2004)
Intensified neoadjuvant chemoradiotherapy (CRT) with capecitabine and irinotecan in patients with locally advanced rectal cancer (LARC): A phase I/II study
Authors: G. Klautke, T. Foitzik, K. Ludwig, E. J. M. Klar, R. Fietkau
Journal: Journal of Clinical Oncology (2004)

3693 Background: This study aimed to determine the maximum tolerated dose (MTD) of capecitabine when given with irinotecan and concurrent radiation as intensified neoadjuvant therapy for LARC. Methods: We treated 10 women and 13 men (14 uT3, 9 uT4, 22 uN+) with a median age of 64 years (range, 48–75). Mean tumor length was 7 cm (range, 3–13). Treatment consisted of conventionally fractionated radiation (1.8 Gy/fx to a total 50.4 Gy) with a local boost of 5.4 Gy depending on the intestinal volume in the radiation field. Concurrent irinotecan 40 mg/m2 was given weekly x6. Capecitabine was given daily throughout treatment (d1–43) at dose levels of 1000, 1300, 1500, and 1650 mg/m2. Patients proceeded to surgery after 4–6 weeks, and postoperative maintenance chemotherapy was given according to the recommendations of the German Cancer Association. Results: DLT occurred at a capecitabine dose level of 1650 mg/m2, with two grade 4 diarrhea and one hand-foot syndrome. There was one sudden cardiac death on day 5 (not related to irinotecan), and another death due to pneumonia six weeks after completion of CRT. The predominant toxicity of CRT was diarrhea (7 grade 3, 2 grade 4). Hematologic toxicity was moderate. Thus far, 12 patients have proceeded to surgery, with one laparotomy being discontinued because of peritoneal spread. R0 resection was possible in 10/11 patients (91%), and 9/11 (82%) had downstaging of their disease by at least one T category. 2/11 patients (18%) had a pCR, 2/11 had only microscopic residues, and the remainder (7/11, 64%) had a PR. Conclusions: The phase II dose of neoadjuvant capecitabine is 1500 mg/m2 daily in combination with weekly doses of irinotecan 40 mg/m2 and concurrent radiation. No significant financial relationships to disclose.
MA12.01 Next Generation Sequencing Based Clinical Framework for Analyses of Treatment Predictive Mutations and Gene Fusions in Lung Cancer
Authors: Kajsa Ericson Lindquist, Anna Karlsson, Per Levéen, Hans Brunnström, Christel Reuterswärd, Karolina Holm, Mats Jönsson, Karin Annersten, Frida Rosengren, Karin Jirström, Jaroslaw Kosieradzki, Lars Ek, Åke Borg, Maria Planck, Göran Jönsson, Johan Staaf
Journal: Journal of Thoracic Oncology (2017)
OA08.06 Brigatinib Activity in Patients with ALK+ NSCLC and Intracranial CNS Metastases in Two Clinical Trials
Authors: Scott Gettinger, Dong-Wan Kim, Marcello Tiseo, Corey Langer, Myung-Ju Ahn, Alice Shaw, Rudolf Huber, Maximilian Hochmair, Sang-We Kim, Lyudmila Bazhenova, Kathryn Gold, Sai-Hong Ou, Howard West, William Reichmann, Jeff Haney, Tim Clackson, Frank Haluska, David Kerstein, D. Ross Camidge
Journal: Journal of Thoracic Oncology (2017)
De novo mutations in SMCHD1 cause Bosma arhinia microphthalmia syndrome and abrogate nasal development
Authors: Christopher T Gordon, Shifeng Xue, Gökhan Yigit, Hicham Filali, Kelan Chen, Nadine Rosin, Koh-ichiro Yoshiura, Myriam Oufadem, Tamara J Beck, Ruth McGowan, Alex C Magee, Janine Altmüller, Camille Dion, Holger Thiele, Alexandra D Gurzau, Peter Nürnberg, Dieter Meschede, Wolfgang Mühlbauer, Nobuhiko Okamoto, Vinod Varghese, Rachel Irving, Sabine Sigaudy, Denise Williams, S Faisal Ahmed, Carine Bonnard, Mung Kei Kong, Ilham Ratbi, Nawfal Fejjal, Meriem Fikri, Siham Chafai Elalaoui, Hallvard Reigstad, Christine Bole-Feysot, Patrick Nitschké, Nicola Ragge, Nicolas Lévy, Gökhan Tunçbilek, Audrey S M Teo, Michael L Cunningham, Abdelaziz Sefiani, Hülya Kayserili, James M Murphy, Chalermpong Chatdokmaiprai, Axel M Hillmer, Duangrurdee Wattanasirichaigoon, Stanislas Lyonnet, Frédérique Magdinier, Asif Javed, Marnie E Blewitt, Jeanne Amiel, Bernd Wollnik, Bruno Reversade
Journal: Nature Genetics (2017)
Importance of CYP2D6 metabolism in the in vitro antiestrogenic activity of toremifene and tamoxifen.
Authors: C. Coss, C. Barrett, J. Kim, C. Li, J. T. Dalton, K. A. Veverka
Journal: Journal of Clinical Oncology (2011)

e13067 Background: Toremifene (TOR) and tamoxifen (TAM) are approved treatments for advanced breast cancer. It has been suggested that poor metabolizers of TAM have worse clinical outcomes than patients who exhibit normal TAM metabolism. TOR and TAM are extensively metabolized by the human cytochrome P450 system (TAM - 3A4 and 2D6; TOR - 3A4). To gain a better understanding of CYP2D6 status and the potential impact on breast cancer activity, we investigated the estrogen and antiestrogen actions of TOR and TAM and their NDM, 4-OH, and 4-OH-NDM metabolites in Ishikawa endometrial and MCF-7 breast cancer cells in vitro. Methods: Estrogen receptor binding affinity was evaluated in vitro using purified ER-LBD and 3H-estradiol. Transactivation activity was determined in HEK-293 cells. TOR, TAM and their N-desmethyl (NDM), 4-OH, and 4-OH-NDM metabolites were evaluated at up to [10 μM] in Ishikawa endometrial and MCF-7 breast cancer cells. Results: TAM and metabolites had similar binding affinity to TOR analogs. The 4-OH and 4-OH-NDM metabolites bound to ER subtypes with 5-50-fold greater affinity and were 50-100 more efficient at ER transactivation than TOR and TAM. Endoxifen (a CYP2D6 product) exhibited the greatest potency of all compounds tested. Estrogen induced Ishikawa cell growth with maximal effects observed at 0.1 nM. TOR and TAM prevented estrogen-mediated agonist effects with similar activity. TOR and TAM had similar antiestrogen activity against Ishikawa cell growth, however, 4-OH metabolites of TAM and TOR are up to 377-fold more potent than their parent drugs. These data are consistent with in vivo studies in intact rats demonstrating TOR and TAM block estrogenic effects on the uterus. TOR and TAM and metabolites were also antagonists in MCF-7 cells, with the order of antiestrogenic potency being 4-OH and 4-OH-NDM metabolites > TOR/TAM and NDM metabolites. Conclusions: Our results provide mechanistic insight into the potential contributions of the 4-OH and 4-OH-NDM metabolites to TOR and TAM activity and perhaps an explanation for the importance of CYP2D6 metabolism to TAM but not TOR clinical outcomes.
Secondary Acute Myeloid Leukemia (AML), Including Therapy-Related AML, Associates with Worse Treatment Outcomes, Than De Novo AML Even After Hematopoietic Stem Cell Transplantation, and Its Unfavorable Behavior Does Not Associated with Functional Activity of p-Glycoprotein, MDR1
Authors: Boram Han, Ha Yeon Lee, Jun Ho Yi, Jun Ho Jang, Kihyun Kim, Hee Jin Kim, Sun-Hee Kim, Chul Won Jung, Dong Hwan (Dennis) Kim
Journal: Blood (2010)
MA10.11 Comparison among Different Radiological Criteria for Assessing Response to Nivolumab in Advanced Non-Small Cell Lung Cancer
Authors: Francesco Grossi, Giovanni Rossi, Erika Rijavec, Giulia Barletta, Federica Biello, Claudia Maggioni, Simone Mennella, Maria Giovanna Dal Bello, Roberta Distefano, Giuseppe Cittadini, Franco Merlo, Carlo Genova
Journal: Journal of Thoracic Oncology (2017)
P1.08-021 Predictors of Post-Operative Mortality in Non-Small Cell Lung Cancer (NSCLC) in a High Mortality Region of the US
Authors: Matthew Smeltzer, Yu-Sheng Lee, Edward Robbins, Nicholas Faris, Chris Mutrie, Meredith Ray, Sam Signore, Carrie Fehnel, Cheryl Houston-Harris, Meghan Meadows, Raymond Osarogiagbon
Journal: Journal of Thoracic Oncology (2017)
Prognostic Impact of JAK2V617F Mutation In MDS: a Matched Case Control Study
Authors: Benoit de Renzis, Eric Wattel, Odile Beyne-Rauzy, Laurent Knoops, Françoise Boyer, Aurélie Cabrespine, Sophie Raynaud, Christian Rose, Jean-Loup Demory, Florence Nguyen-Khac, Lionel Ades, Gerard Tertian, Romain Guièze, Jean Christophe Ianotto, Olivier Tournilhac, Dominique Bordessoule, Jean-Yves Cahn, Michaela Fontenay, Jean-Jacques Kiladjian, Pierre Fenaux
Journal: Blood (2010)
OA19.07 Difference of Postoperative Survival Due to the Type of EGFR Gene Mutation in Surgically Resected Lung Adenocarcinomas
Authors: Kazuki Hayasaka, Satoshi Shiono, Yuki Matsumura, Naoki Yanagawa, Hiroyuki Suzuki, Jiro Abe, Motoyasu Sagawa, Akira Sakurada, Masato Katahira, Yuichiro Machida, Satomi Takahash, Yoshinori Okada
Journal: Journal of Thoracic Oncology (2017)
P3.04-004 The Risk Factor of the Thrombus Formation in Pulmonary Vein Stump after Left Upper Lobectomy for Lung Cancer
Authors: Reiko Shimizu, Shoko Hayashi, Kiyomichi Mizuno, Yoshiyuki Yasuura, Hiroyuki Kayata, Hideaki Kojima, Shoji Takahashi, Mitsuhiro Isaka, Masahiro Endo, Yasuhisa Ohde
Journal: Journal of Thoracic Oncology (2017)
S49 The role of platelet-derived TGFβ in pulmonary fibrosis
Authors: DLW Chong, C Rebeyrol, A Khawaja, EJ Forty, N Kanda, CJ Scotton, JC Porter
Journal: Thorax (2016)

<h3>Background</h3> Pulmonary Fibrosis (PF) is characterised by abnormal wound healing involving fibroblast proliferation, myofibroblast differentiation and increased extracellular matrix deposition. TGFβ is an important driving force in fibrotic disease, however the source of this cytokine in PF is ill-defined. Platelets can release large amounts of TGFβ, and we, and others, have shown platelet deposition in the lungs of patients with idiopathic pulmonary fibrosis (IPF), although the role of these cells in PF is unknown. <h3>Hypothesis</h3> We propose that platelet aggregation and release of platelet-derived TGFβ contributes to the aberrant wound healing in fibroproliferative lung disease. <h3>Methods</h3> We used a double-transgenic mouse with megakaryocytic-specific deletion of TGFβ (PF4-Cre<sup>+</sup>/Tgfb1<sup>fl</sup>) and hence platelets lacking TGFβ. Knockout (KO) mice and wildtype (WT) littermate controls were subjected to the experimental model of lung fibrosis induced by oropharyngeal bleomycin administration. Lung tissue and broncho-alveolar lavage fluid (BALF) were investigated at 6, 21 or 28 days post-bleomycin. Complementary <i>in vitro</i> studies were performed on isolated neutrophils to investigate the effects of platelet-derived TGFβ in chemotaxis assays. <h3>Results</h3> <i>In vitro</i>: Platelet-derived TGFβ was shown to be a potent neutrophil chemoattractant with maximal effect at 1ng/ml. <i>In vivo</i>: At 6 days after bleomycin treatment, neutrophils and macrophages were significantly elevated in the lung and BALF in both WT and KO animals as measured by flow cytometric analysis. No significant difference in the percentage or total cell numbers was found between WT or KO mice. At 21 days post-bleomycin, the lungs developed large fibrotic lesions when examined by micro-CT. Bleomycin-treated KO mice exhibited an attenuated fibrotic response compared with WT animals (26.9 vs. 19.6%), although not reaching statistical significance. During the wound resolution phase at 28 days post treatment, the degree of fibrosis between WT and KO animals was very similar (9.56 vs. 9.84%) as determined by micro-CT analysis. <h3>Conclusion</h3> Our data suggest that despite being a potent neutrophil chemoattractant <i>in vitro</i>, platelet-derived TGFβ <i>in vivo </i>is not a major driving force during the inflammatory or resolution phases of our PF animal model, but may contribute to the development of fibrotic disease. This will be the subject of further study.
Combined endoscopic and surgical covered stent placement: a new tailored treatment for enteroatmospheric fistula in patients with terminal ileostomy
Authors: Lionel Rebibo, Adrien Wacrenier, Henri Thiebault, Richard Delcenserie, Jean-Marc Regimbeau
Journal: Endoscopy (2017)

An enteroatmospheric fistula (EAF) is defined as the presence of an enteric fistula in the middle of an open abdomen with no overlying soft tissue [1].
Patterns of toxicity for treatment of anal carcinoma: A quality improvement initiative.
Authors: N. K. LoConte, K. K. Rothering, D. Mulkerin, W. R. Schelman, M. A. Ritter, S. J. Lubner
Journal: Journal of Clinical Oncology (2011)

e14513 Background: Over 18 months, our institution treated 20 patients (pts) with anal squamous cell carcinoma. We have a unified approach to the treatment of these pts with similar chemotherapy and radiation approaches, providing an ideal situation to analyze toxicity. Methods: Charts were abstracted for the pts treated for anal cancer from January 2009 through June 2010. Results: Twenty pts were treated, 16 were female (80%), 2 (10%) were HIV positive. All had their oncology care at one institution. All but two were treated with mitomycin and 5-FU, one was treated with cisplatin alone and one with cisplatin/5FU. The mean age was 59 yrs (range 42-78 yrs). The dominant stage was T2N0M0 (30%) but all T and N stages were present in at least one pt. There were 17 total hospital admissions, with 11 pts having one admit and 3 pts having multiple admits. The length of stay ranged from 7 to 18 days with a mean of 12 days. 65% of the admissions were for infection (50% neutropenic fever). Other toxicity is presented in the table. 15% of patients were discharged to a nursing home. Weight loss was common, with a range of 3 to 27 lb and a mean of 9.6 lb per patient. If a pt lost weight, the mean was 13.7 lb. There was one death from presumed sepsis. Conclusions: This study demonstrates that treatment for anal cancer outside of a clinical trial setting is considerably toxic. Based on these results, we have added fluconazole, G-CSF and ranitidine as part of our standard treatment of anal cancer patients. Our patients are informed that hospitalization is likely with this treatment. Continued multidisciplinary management of these patients is crucial to successfully managing toxicity. Toxicity n % Mucositis, grade 3+ 11 55 Oral candidiasis, any grade 9 45 Diarrhea, grade 3+ 17 85 Nausea, any grade 6 30 Vomiting, any grade 7 35 Outpatient hydration 9 45 Positive blood cultures 5 20 PRBC transfusion 8 35 Dose modification 11 55